Many clinical trial status discrepancies identified between ClinicalTrials.gov and EUCTR

Approximately one sixth of clinical trials registered on both ClinicalTrials.gov and the EU Clinical Trials Register (EUCTR) have discrepancies in their completion status, according to a study published March 7, 2018 in the open-access journal PLOS ONE by Jessica Fleminger and Ben Goldacre from the University of Oxford, UK.

Trial registries are important sources of information for clinicians and researchers, since they provide information on what trial results are pending or already available. While building OpenTrials, an open database that aims to link all publicly available information from all clinical trial registries, the authors of this study identified multiple errors, omissions and discrepancies between different registries. These differences prompted the researchers to investigate the prevalence of incorrect completion statuses between two major registries, the EU Clinical Trials Register (EUCTR) and ClinicalTrials.gov.

The researchers analyzed 10,492 clinical trials that were registered on both ClinicalTrials.gov and EUCTR, examining their trial completion status and reporting status for discrepancies. They found that 16.2% of dual registered trials had discrepant completion statuses and 33.9% of dual-registered trials listed as 'ongoing' on EUCTR were listed as 'completed' on ClinicalTrials.gov.

The researchers suggest that the prevalence of incorrect statuses on trial entries could mean that they are excluded from studies looking at publication bias or systematic reviews pooling together clinical data from different clinical trials. While it is unclear whether researchers, registry owners, or both are responsible for the errors, the authors recommend that researchers identifying discrepancies should request clarifications from the trialists, and registry owners should undertake simple cross-checks of data to ensure that the completion status is accurate.

"Trial registries are important public documents: doctors, researchers, and patients rely on the information that trialists post about their clinical trial," says Ben Goldacre. "Concerningly, we now show that this data is commonly inaccurate."

Jessica Fleminger, Ben Goldacre.
Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register.
PLoS ONE 13(3): e0193088. doi: 10.1371/journal.pone.0193088.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...